Personalised randomised controlled trial designs-a new paradigm to define optimal treatments for carbapenem-resistant infections. (2021)

First Author: Walker AS

Attributed to: Syndromic infections funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1473-3099(20)30791-x

PubMed Identifier: 33894130

Publication URI: http://europepmc.org/abstract/MED/33894130

Type: Journal Article/Review

Volume: 21

Parent Publication: The Lancet. Infectious diseases

Issue: 6

ISSN: 1473-3099